Given the industry’s exponential growth over the past couple of decades, it is no surprise tech penny stocks continue to be some of the most profitable investments with a risk-reward ratio skewed toward a buy. With this in mind, this article dives deep into 3 of the tech penny stocks dominating the top gainers’ list today – Apollo Endosurgery Inc (NASDAQ: APEN), Verve Therapeutics, Inc. (NASDAQ: VERV) and Tyra Biosciences, Inc. (NASDAQ: TYRA)


On July 13th, Apollo Endosurgery Inc (NASDAQ: APEN) announced that it has received FDA Grants De Novo Marketing Authorization for its flagship endoscopic systems – Apollo Endosurgery for Apollo ESG(TM) and Apollo REVISE(TM) – which are developed to treat patients with Obesity. In light of the fact that these are the first and only devices authorized by the FDA for endoscopic sleeve gastroplasty (ESG) and endoscopic bariatric revision, investors are bullish this step will facilitate major growth for the company in the next few months.

In addition, Chas McKhann – APEN’s President and CEO – believes that:

The authorization of these new endoscopic systems represents a major step forward in addressing the global obesity epidemic.”

In fact, the announcement has already prompted an overnight 12% increase in APEN’s shares and it shows no sign of stopping. As a medical technology company, APEN is well-known for its next-generation devices that treat a variety of gastrointestinal conditions and advance therapeutic endoscopy.

With its device-based therapies being an alternative to invasive surgical procedures, APEN’s systems are designed to lower complication rates and reduce total healthcare costs. Not only that, but in a randomized controlled trial, the ESG procedure demonstrated safety and effectiveness with durability for up to 2 years. With these competitive edges, APEN could be well-positioned to capitalize on a massive market!

Following its run-up, APEN is trading at its resistance of $5.02 with support at 4.12 and 3.69. Accumulation has seen a steep downfall after being steady for the past couple of weeks, meanwhile, the MACD is bullish to the upside. Similarly, the RSI is at 80 and continues to trend upwards – indicating the stock is currently overbought.

Given that the stock is currently trading at its resistance with a high RSI, bullish investors could wait for a pullback before securing a position on APEN. Want alerts on the best entry points on APEN and other promising penny stocks? Sign up here!


As a biotechnology company Verve Therapeutics, Inc. (NASDAQ: VERV) is pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines. On July 12th, the company announced that the first patient in its heart-1 clinical trial has been dosed with VERVE-101 – a novel, investigational gene editing medicine.

Bullish on this step, Sekar Kathiresan, M.D. – co-founder & CEO – said that:

The dosing of the first human with such an investigational base editing medicine represents a significant achievement by our team and for the field of gene editing.”

VERVE-101 is developed and designed to be a single-course treatment that permanently turns off the PCSK9 gene in the liver to reduce disease-driving low-density lipoprotein cholesterol (LDL-C).  Initially, the VERVE-101 treatment is being developed for patients with heterozygous familial hypercholesterolemia (HeFH) – a prevalent and potentially life-threatening subtype of atherosclerotic cardiovascular disease (ASCVD)

Andrew Bellinger, M.D., Ph.D. – chief scientific and medical officer – believes this treatment has huge potential. He highlights the growing need for VERVE-101 saying:

With the current standard of care treatment for HeFH, less than 20% of patients achieve LDL-C goal levels due to the limitations of the chronic model which requires rigorous patient adherence, regular health care access, and extensive health care infrastructure.”

With this in mind, VERV’s VERVE-101 will position the company to capitalize on this extremely lucrative underserved market. It is clear investors are quickly realizing the untapped potential of the company following this announcement as shown by the massive increase in its PPS on Wednesday.

Cooling off after its run-up, VERV is now trading at $24.3 with a new resistance of 26.03. The stock has support at 20.46 and 15.46. Accumulation has been climbing steadily but is recently witnessing a slight dip. However, the MACD is on a recent bullish crossover and the RSI is now cooling off despite being overbought at 82 beginning of the trading day.


TYRA has caught investors’ attention after seeing relatively consistent gains for the past week. Ever since the company released impressive financial results, investors have been watching this play closely…

The precision oncology company, Tyra Biosciences, Inc. (NASDAQ: TYRA), is focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Since Q1 2022, the company has shown major corporate progress. Aside from well-capitalizing with cash and cash equivalents of $292.5 million, TYRA is also working on enhancing its pipeline.

With the company’s ongoing developments, CEO Todd Harris believes this is the perfect time for TYRA to prepare for a successful transition to a clinical-stage company. He assures investors of these efforts saying: “We look forward to filing INDs for both TYRA-300 and TYRA-200 this year while continuing to advance our platform and pipeline”

Following its run-up, TYRA is now trading at $10.52 with a new resistance at 11.39. The stock shows support at 7.05 and 6.3. Accumulation has been fluctuating heavily and the MACD is bullish but is on the verge of a bearish crossover. Similar to its accumulation, the RSI is fluctuating but is now holding at 54 – indicating the stock is currently stable to trade.


Lucrative markets, untapped potential and major catalysts – a recipe for explosive returns. Clearly, there are major gains to be made when it comes to trading tech penny stocks – and these recent run-ups are living proof! Wanna get in on the BEST penny stocks on the NASDAQ & NYSE? We’ve got your back!

As always, good luck to all (except the shorts)!


Disclosure: We have no business relationship with any company whose stock is mentioned in this video. Viral Stocks is not an investment advisor and this video does not provide investment advice. Always do your own research, make your own investment decisions, or consult with your nearest financial advisor. This video is not a solicitation or recommendation to buy, sell, or hold securities. This video is our opinion and is meant for informational and educational purposes only and does not provide investment advice. Past performance is not indicative of future performance.

Leave a Reply

Your email address will not be published.